Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38,035 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer.
Rugo HS, Campone M, Amadori D, Aldrighetti D, Conte P, Wardley A, Villanueva C, Melisko M, McHenry MB, Liu D, Lee F, Pivot X. Rugo HS, et al. Among authors: liu d. Breast Cancer Res Treat. 2013 Jun;139(2):411-9. doi: 10.1007/s10549-013-2552-8. Epub 2013 May 7. Breast Cancer Res Treat. 2013. PMID: 23649189 Free PMC article. Clinical Trial.
Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker.
Saura C, Tseng LM, Chan S, Chacko RT, Campone M, Manikhas A, Nag SM, Leichman CG, Dasappa L, Fasching PA, Hurtado de Mendoza F, Symmans WF, Liu D, Mukhopadhyay P, Horak C, Xing G, Pusztai L. Saura C, et al. Among authors: liu d. Oncologist. 2013;18(7):787-94. doi: 10.1634/theoncologist.2013-0075. Epub 2013 Jul 12. Oncologist. 2013. PMID: 23853246 Free PMC article. Clinical Trial.
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR; CA184-043 Investigators. Kwon ED, et al. Among authors: liu d. Lancet Oncol. 2014 Jun;15(7):700-12. doi: 10.1016/S1470-2045(14)70189-5. Epub 2014 May 13. Lancet Oncol. 2014. PMID: 24831977 Free PMC article. Clinical Trial.
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA; RELEVANCE Trial Investigators. Morschhauser F, et al. Among authors: liu d. N Engl J Med. 2018 Sep 6;379(10):934-947. doi: 10.1056/NEJMoa1805104. N Engl J Med. 2018. PMID: 30184451 Free PMC article. Clinical Trial.
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.
Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, Zhang H, Offner F, Scheliga A, Nowakowski GS, Pinto A, Re F, Fogliatto LM, Scheinberg P, Flinn IW, Moreira C, Cabeçadas J, Liu D, Kalambakas S, Fustier P, Wu C, Gribben JG; AUGMENT Trial Investigators. Leonard JP, et al. Among authors: liu d. J Clin Oncol. 2019 May 10;37(14):1188-1199. doi: 10.1200/JCO.19.00010. Epub 2019 Mar 21. J Clin Oncol. 2019. PMID: 30897038 Free PMC article. Clinical Trial.
T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer.
Obradovic AZ, Dallos MC, Zahurak ML, Partin AW, Schaeffer EM, Ross AE, Allaf ME, Nirschl TR, Liu D, Chapman CG, O'Neal T, Cao H, Durham JN, Guner G, Baena-Del Valle JA, Ertunc O, De Marzo AM, Antonarakis ES, Drake CG. Obradovic AZ, et al. Among authors: liu d. Clin Cancer Res. 2020 Jul 1;26(13):3182-3192. doi: 10.1158/1078-0432.CCR-19-3372. Epub 2020 Mar 15. Clin Cancer Res. 2020. PMID: 32173650 Free PMC article.
Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab.
Maloney AK, Giobbie-Hurder A, Katukota N, Fogarasi MC, Ott PA, Hodi FS, Sussman TA, Silk AW, Haq R, Liu D, Insco M, Buchbinder EI. Maloney AK, et al. Among authors: liu d. J Immunother Cancer. 2024 Aug 28;12(8):e009061. doi: 10.1136/jitc-2024-009061. J Immunother Cancer. 2024. PMID: 39209453 Free PMC article.
Online registry of neonatal necrotising enterocolitis in Shenzhen: protocol for a multicentre, prospective, open, observational cohort study.
Guo X, Feng J, Zhao X, Ying E, Liu D, Tu H, Yan Y, Huang H, Li X, Chen X, Zeng S, Lin Y, Zhou K, Zhang L, Yuan S, Zhang Q, Lin F, Dou L, Chai Y, Cai Y, Liu R, Bai L, Chen T, Chen Z, Wang Z, Li Y, Gong X, Fang X, Zhang A, Li G, Liao Z, Chen C, Chen J, Guo Y, Liu Y, Tang H, Lin H, Rao DD. Guo X, et al. Among authors: liu d. BMJ Open. 2024 Nov 24;14(11):e091290. doi: 10.1136/bmjopen-2024-091290. BMJ Open. 2024. PMID: 39581716
38,035 results
You have reached the last available page of results. Please see the User Guide for more information.